Full Press Release Details
Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board.
IMMP
Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
Key Takeaway: Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
Price reaction · baseline $1.89 (2022-09-09 close) · 3 other IMMP headline(s) in the window, move may be shared
day 0 close
+0.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)